Lymphocyte ectoenzymes in childhood idiopathic nephrotic syndrome.
Lymphocyte ectoenzymes with immunomodulatory function were investigated in 11 children with minimal change disease (MCD), 9 with primary focal segmental glomerulosclerosis (FSGS), and 17 age- and sex-matched healthy children. Basal, concanavalin A (Con A)-, and pokeweed mitogen (PWM)-stimulated lymphocyte ecto-5'-nucleotidase (5'-Nu), dipeptidyl peptidase IV (DPP IV), and alkaline phosphodiesterase I (APD) activities were determined. In MCD relapse ecto-APD activity of unstimulated lymphocytes was higher than controls. Ecto-APD of Con A-stimulated lymphocytes was below controls (23.0, range 7.2-48.7 nmol/min per 10(6) lymphocytes) in all active MCD (18.7, range 7.6-32.6), during corticosteroid treatment (14.6, range 4.5-54), and in remission (13.1, range 6.1-19.6), but was significant only in remission. Con A-stimulated DPP IV was significantly lower from controls (53.8, range 19.3-85.7 nmol/min per 10(6) lymphocytes) in all active MCD (38.1, range 10.8-82.1), during treatment (37.5, range 20.2-58.7), and in remission (39.4, range 24.3-69.6). In FSGS, unstimulated lymphocyte ecto-APD activity was greater than controls. However, Con A-stimulated lymphocyte ecto-APD and DPP IV activities were not significantly different from controls. Con A stimulation of lymphocyte ecto-APD and DPP IV activity was significantly reduced in MCD relapse and in remission, but not in FSGS. Basal, Con A-, and PWM-stimulated ecto-5'-Nu in MCD and FSGS were not different from controls. These results suggest a role for abnormal T cell function in MCD but not in FSGS. The difference in mitogen-stimulated expression of these ectoenzymes suggests a different pathogenesis of childhood MCD and primary FSGS.
Stefanović
V
V
Institute of Nephrology and Hemodialysis, Faculty of Medicine, Nis, Yugoslavia.
Golubović
E
E
Vlahović
P
P
Mitić-Zlatković
M
M
D015720:5'-Nucleotidase / Q000097:blood*; D000293:Adolescent; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D003208:Concanavalin A / Q000494:pharmacology; D018819:Dipeptidyl Peptidase 4 / Q000097:blood*; D004789:Enzyme Activation; D005260:Female; D005919:Glomerular Filtration Rate; D005923:Glomerulosclerosis, Focal Segmental / Q000097:blood / Q000201:enzymology* / Q000503:physiopathology; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D009402:Nephrosis, Lipoid / Q000097:blood / Q000201:enzymology* / Q000503:physiopathology; D043264:Phosphodiesterase I; D010727:Phosphoric Diester Hydrolases / Q000097:blood*; D011043:Pokeweed Mitogens / Q000494:pharmacology; D011507:Proteinuria / Q000097:blood / Q000201:enzymology / Q000503:physiopathology
D011043:Pokeweed Mitogens; D003208:Concanavalin A; D015720:5'-Nucleotidase; D010727:Phosphoric Diester Hydrolases; D043264:Phosphodiesterase I; D018819:Dipeptidyl Peptidase 4